Two Pew Scholars Receive New Innovator Award From NIH

Navigate to:

Two Pew Scholars Receive New Innovator Award From NIH

Washington, D.C. - Drs. Ekaterina Heldwein and Michael Rape, 2007 Pew Scholars in the Biomedical Sciences, each will receive $1.5 million over a five-year period to further their innovative biomedical research as part of the National Institutes of Health's (NIH) New Innovator Award Program.

The award is part of an NIH Roadmap for Medical Research initiative that tests new approaches to supporting research.

Both Heldwein and Rape were selected earlier this year as Pew Scholars based upon the same research work for which NIH subsequently recognized them.  The Pew program provides crucial and flexible support to the scholars and encourages awardees to be entrepreneurial and innovative in their research.

Dr. Heldwein, an assistant professor of microbiology and molecular biology at Tufts University School of Medicine, hopes to determine, at an atomic level, how herpes viruses enter human cells.  Her work could aid in the design of drugs that could be used to prevent or treat infection with herpes viruses.

Dr. Rape, an assistant professor at the University of California at Berkeley, hopes to decipher how one important piece of cellular machinery, the anaphase-promoting complex (APC), allows cells to divide and differentiate into all the different tissues of the body during embryonic development.  His work could help identify specific inhibitors that would thwart the proliferation of cancer cells or promote the regeneration of injured tissue, particularly in the central nervous system.  Such inhibitors could one day form the basis of new treatment drugs.

The Pew Scholars in the Biomedical Sciences program was launched in 1985 to provide crucial support to investigators in the early- to mid-stages of their careers who show outstanding promise in the basic and clinical sciences.  Since then, Pew has invested more than $100 million to fund nearly 400 scholars.

For more information about the NIH Roadmap initiative, please visit the Web site at http://nihroadmap.nih.gov.

America’s Overdose Crisis
America’s Overdose Crisis

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Quick View

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.